Neuropacs Parkinsonian Syndromes
Overview
Neuropacs Parkinsonian Syndromes (by Neuropacs) is an AI-powered, prescription-only software application designed to assist in differentiating Parkinson’s disease (PD) from atypical parkinsonian syndromes, specifically multiple system atrophy Parkinsonian variant (MSAp) and progressive supranuclear palsy (PSP). The tool has received FDA De Novo classification (DEN240071) as a Parkinsonian syndrome diagnostic aid.
The software is intended for use by neurologists and neuroradiologists evaluating patients aged 40 years and older who present with parkinsonian symptoms. It is designed as an adjunctive diagnostic aid to provide supplemental information alongside standard neurological assessments, rather than as a standalone diagnostic tool.
Clinical Workflow Integration:
- The platform operates via a secure, cloud-based workflow.
- It utilizes standard, non-invasive diffusion MRI sequences acquired on 3 Tesla clinical MRI systems from major manufacturers, including Siemens, GE Healthcare, and Philips.
- The system processes the imaging data using a validated free-water imaging (FWI) model and machine learning algorithms to analyze degenerative brain patterns.
- It automatically generates a classification report detailing the degenerative patterns associated with MSAp and PSP to support clinical decision-making and patient stratification.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven diagnostics trained on harmonized multi-site data
- Exclusive, patented Free-Water Imaging (FWI) technology
- Up to 96% accuracy in distinguishing PD from MSAp and PSP
- Quantitative disease insights (measures severity, rate, and state of degeneration)
- Next-level sensitivity for detecting subtle microstructural changes
- Cloud-based workflow for seamless integration
- Supports clinical decision-making and clinical trial outcomes
- Analyzes patient-specific diffusion MRI data
- Compatible with standard diffusion MRI sequences on 3T MRI systems (Siemens, GE Healthcare, Philips)
- Generates classification reports for Parkinsonian syndromes
Use Cases
- Differentiating Parkinson's disease from atypical parkinsonian syndromes (MSAp, PSP)
- Improving diagnostic accuracy in neurodegenerative diseases
- Patient stratification for neurodegenerative clinical trials
- Measuring quantitative progression markers for efficacy assessment in trials
- Optimizing clinical endpoint achievement in trials
- Supporting neuroradiologists and neurologists in clinical assessment
Details
| Category | Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Cloud-based |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Cleared AI-estimated Neuropacs™ received De Novo classification from the FDA in April 2026, establishing a new regulatory category for "Parkinsonian syndrome diagnostic aid" and marking it as the first device cleared under this classification. |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology, Radiology |
What the Web Says
Neuropacs Parkinsonian Syndromes is an AI-powered diagnostic software that assists clinicians in differentiating Parkinson's disease (PD) from atypical parkinsonian syndromes like Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). It utilizes diffusion MRI data and machine learning algorithms to generate a classification report, providing supplemental information for neuroradiologists and neurologists. The software recently received De Novo classification from the FDA, establishing a new regulatory category for this type of diagnostic aid.
Overall: PositiveStrengths
- High accuracy in differentiating Parkinson's disease from atypical parkinsonism (96%).
- Even higher accuracy in distinguishing between MSA and PSP (98%).
- Diagnoses confirmed by post-mortem autopsy in a high percentage of cases (93.9% to 94%).
- Non-invasive and radiotracer-free, using standard diffusion MRI sequences.
- Integrates with existing imaging workflows through a cloud-based analysis platform.
- Addresses a critical clinical challenge of accurate early differentiation of parkinsonian syndromes.
Limitations
- Intended as a supplemental tool, not a standalone diagnostic.
- Requires interpretation in conjunction with clinical evaluation and other diagnostic testing.
- Does not rule out other potential causes of Parkinsonism symptoms.
- Limited information available from independent tech reviewers or platforms like G2 and Capterra at this early stage.
- Reddit discussions highlight the general difficulty in diagnosing Parkinson's and atypical parkinsonism, but no specific reviews of Neuropacs were found.
Based on reviews from: Practical Neurology, ACNR, Business Wire, UF Innovate, Morningstar, BioSpace, Reddit
Last updated: 2026-07-12
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Neuropacs Parkinsonian Syndromes
Videos
Product demos, reviews, and walkthroughs for Neuropacs Parkinsonian Syndromes.
How Neuropacs helps neurologists differentiate types of Parkinsonism
neuropacs
Frequently Asked Questions
Investors who backed Neuropacs Parkinsonian Syndromes
Funded through the company that built this tool.
